<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710915</url>
  </required_header>
  <id_info>
    <org_study_id>HG146-I-CRP-1.0</org_study_id>
    <nct_id>NCT03710915</nct_id>
  </id_info>
  <brief_title>A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HitGen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HitGen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the tolerability and safety of HG146 capsule in patients
      with multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is mainly designed to evaluate the tolerability and safety of HG146 capsule in
      patients with multiple myeloma. Secondly, to get pharmacokinetic data and preliminary
      efficacy of HG146 capsule in human.

      This study adopts the traditional design of &quot;3 + 3&quot; dose escalation. The starting dose is 5
      mg and subsequent dose group is respectively for 10, 15 and 20 mg. For each dosing group,
      subjects are administered orally HG146 every other day for two weeks, followed by one week of
      rest with 21-day as one treatment cycle. Patients will be treated for 4 cycles or disease
      progression or unacceptable toxicities, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2018</start_date>
  <completion_date type="Anticipated">July 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Drug: HG146 capsule HG146 capsule is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
Other Name: HG280146, HG0146, HG280146, HG280146-P1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of HG146</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To determine the maximum tolerated dose of HG146 in relapsed and refractory multiple myeloma patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>In cycle 1 (each cycle is 21 days)</time_frame>
    <description>To determine the Peak Plasma Concentration of HG146.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>In the middle of cycle 1 (each cycle is 21 days)</time_frame>
    <description>To determine the Area under the plasma concentration versus time curve of HG146.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Peak Concentration (Tmax)</measure>
    <time_frame>In the middle of cycle 1 (each cycle is 21 days)</time_frame>
    <description>To determine the time of peak concentration of HG146.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T1/2)</measure>
    <time_frame>In the middle of cycle 1 (each cycle is 21 days)</time_frame>
    <description>To determine the half-life of HG146.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events related to treatments</measure>
    <time_frame>Up to 21 days after last dose</time_frame>
    <description>To evaluate the incidence of adverse events that are related to treatments in relapsed and refractory myeloma patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities related to treatments</measure>
    <time_frame>Up to 1 month after last dose</time_frame>
    <description>To evaluate the incidence of laboratory abnormalities that are related to treatments in relapsed and refractory myeloma patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Relapsed and Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>HG146 capsule treat multiple myeloma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: 5/10/15/20 mg HG146 capsule 5 mg starting dose taken orally on Day 1, 3, 5, 7, 9, 11, 13 of each cycle, and off drug for 8 days (3 weeks).
Intervention: Drug: HG146 capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HG146</intervention_name>
    <description>HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.</description>
    <arm_group_label>HG146 capsule treat multiple myeloma</arm_group_label>
    <other_name>HG280146, HG0146, HG280146, HG280146-P1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of multiple myeloma requiring systemic therapy (International Myeloma
             Working Group [IMWG]) and 2 cycles of treatment including proteasome inhibitors and/or
             immunomodulators.

          -  Serum M protein≥ 10.0g / L, or urine M protein ≥ 200mg / 24h.

          -  Not suitable for autologous bone marrow transplantation or refuse autologous bone
             marrow transplantation or relapse after autologous bone marrow transplantation.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or 2.

          -  Expected survival of ≥3 months.

          -  Hemoglobin ≥ 80 g/L, Platelet≥75×10^9/L, Absolute Neutrophil Count≧1.0×109/L (1000
             cells/mm3), Prothrombin time(PT) and activated partial thromboplastin time ≤ 2 x Upper
             Limit of Normal (ULN).

          -  Bilirubin in serum＜1.5*ULN (2.0mg/dL/20mg/L/34.2μmol/L); glutamic-pyruvic transaminase
             (ALT) and/or Aspartate Aminotransferase (AST)≤3*ULN (upper limit of normal).

          -  Normal electrocardiogram, echocardiography and myocardial enzyme spectrumCalibration
             of blood calcium concentration≤ULN.

          -  Men and women, Non-pregnant women who did not consider giving birth during the trial
             or five years after the end of the trial.

          -  The patient is able to swallow the capsule.

          -  Patients must provide written consent.

        Exclusion Criteria:

          -  Severe allergies to the study drug or any of its excipients.

          -  The possibility of gene toxicity, mutagenesis and teratogenicity.

          -  Men and women who did not have sperm or egg cells stored in vitro before the trial and
             who planned to have children again within five years.

          -  Pregnant or lactating women.

          -  Perform autologous bone marrow transplantation 3 months before admission.

          -  Receive allogeneic bone marrow transplantation.

          -  Use HDAC inhibitors before.

          -  Two weeks prior to admission, received radiotherapy or bone marrow suppressive
             chemotherapy or biological treatment.

          -  Patients with history of other malignant tumors, except the tumor is in remission and
             has not been treated for at least 5 years.

          -  Patients with dysphagia or oral absorption disorder.

          -  The investigators determine the conditions not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The West China Hospital of Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Shen, M.S</last_name>
    <phone>+86 2885197385</phone>
    <phone_ext>8211</phone_ext>
    <email>jie.shen@hitgen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu-mei Che, M.S</last_name>
    <phone>+86 2885197385</phone>
    <phone_ext>8211</phone_ext>
    <email>ym.che@hitgen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HitGen Inc</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Shen, M.S</last_name>
      <phone>+86 2885197385</phone>
      <phone_ext>8211</phone_ext>
      <email>jie.shen@hitgen.com</email>
    </contact>
    <contact_backup>
      <last_name>Yu-mei Che, M.S</last_name>
      <phone>+86 2885197385</phone>
      <phone_ext>8211</phone_ext>
      <email>ym.che@hitgen.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ting Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Huang B, Lu J, Wang X, Xiao Y, Zhao Y, Huang H, Liu J, Chen M, Gu J, Yuan S, Zheng D, Li Y, Huang X, Li J. Prognostic value of lactate dehydrogenase in Chinese patients with newly diagnosed transplant eligible multiple myeloma. Leuk Lymphoma. 2017 Jul;58(7):1740-1742. doi: 10.1080/10428194.2016.1252975. Epub 2016 Nov 23.</citation>
    <PMID>27881052</PMID>
  </reference>
  <reference>
    <citation>Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J; Chinese Medical Doctor Association Hematology Branch. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014 Aug 15;4:e239. doi: 10.1038/bcj.2014.55.</citation>
    <PMID>25127393</PMID>
  </reference>
  <reference>
    <citation>Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.</citation>
    <PMID>25439696</PMID>
  </reference>
  <reference>
    <citation>Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842-54.</citation>
    <PMID>1182674</PMID>
  </reference>
  <reference>
    <citation>Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.</citation>
    <PMID>26240224</PMID>
  </reference>
  <reference>
    <citation>Lu J, Lee JH, Huang SY, Qiu L, Lee JJ, Liu T, Yoon SS, Kim K, Shen ZX, Eom HS, Chen WM, Min CK, Kim HJ, Lee JO, Kwak JY, Yiu W, Chen G, Ervin-Haynes A, Hulin C, Facon T. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol. 2017 Mar;176(5):743-749. doi: 10.1111/bjh.14465. Epub 2017 Jan 20.</citation>
    <PMID>28106903</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDAC inhibitor</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>HG146</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

